Toxicity due to calcium-channel blockers (CCBs) or β-blockers results in significant morbidity and mortality. [9] The manifestations of toxicity are generally extensions of the drugs' pharmacologic ...

Calcium channel blocker toxicity represents a significant clinical challenge owing to its multifaceted pathophysiology and potential to precipitate life‐threatening cardiovascular compromise. Overdose ...

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...